Hikma Looks To Be Partner Of Choice In MENA Region Via Acquisition Of Promopharm
This article was originally published in PharmAsia News
Executive Summary
Jordanian drug maker Hikma Pharmaceuticals PLC acquired 63.9% of Moroccan branded generics firm Promopharm SA Oct. 3 in a cash deal worth $111.2 million. The acquisition gives Hikma access to the fourth largest pharmaceutical market in the Middle East and North Africa, additional manufacturing capacity and capability, and a perhaps stronger claim to its goal of being a partner of choice for multinationals across the MENA region
You may also be interested in...
Jordan’s Hikma Sails On Strong Winds From Injectables, But Generics Lag
A slower than expected remediation process with U.S. FDA for its Eatontown, New Jersey, plant has cast a shadow on Hikma’s generics business and may lead to a restructuring or even sale of the unit.
Jordan’s Hikma Continues Buying Spree In MENA With Egypt Acquisition
Hikma will acquire Egypt’s EPCI as part of its strategy to grow in the Middle East and North Africa region. It has its sites on Turkey, but says acquisition targets are too pricey for now.
Quintiles Continues Eastward Push, Looks To Russia And Middle East For Growth
The U.S. CRO sees opportunities to align with young, domestic biopharma companies in emerging markets.